盐酸曲美他嗪治疗2型糖尿病合并慢性心功能不全患者的临床效果分析

Abstract
Figure/Table
References (19)
Related Citation (15)

Download: PDF (0 KB) HTML (37 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Trimetazidine Dihydrochloride in the treatment of patients with type 2 diabetes mellitus (DM)complicated with chronic heart failure.Methods The clinical data of 92 patients with type 2 DM and chronic heart failure treated in the outpatient of our hospital from February 2014 to February 2017 were analyzed.They were divided into control group(32 cases)and combined treatment group(60 cases)acccording to the random paper method.The control group was given conventional therapy and the combined treatment group was treated with Trimetazidine Dihydrochloride on the basis of the control group.The levels of left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),fasting blood glucose(FBG),glycosylated hemoglobin(HbA1c)before and after treatment,and clinical effect after treatment of two groups were compared.There were no significant differences in levels of LVEF,LVEDD,and LVESD between two groups before treatment(P＞0.05).The levels of LVEF in two groups after treatment were higher than that before treatment,the levels of LVEDD and LVESD were lower than those before treatment,and the differences were statistically significant(P＜0.05).The level of LVEF in the combined treatment group after treatment was higher than that in the control group,the levels of LVEDD and LVESD were lower than those in the control group,and the differences were statistically significant(P＜0.05).There were no significant differences in levels of FBG and HbA1c between two groups before treatment(P＞0.05).The levels of FBG and HbA1c in two groups after treatment were lower than those before treatment,and the difference was statistically significant(P＜0.05).The levels of FBG and HbA1c in the combined treatment group after treatment were lower than those in the control group,and the difference was statistically significant(P＜0.05).The total effective rate of treatment in the combined treatment group was higher than that in the control group,and the difference was statistically significant(P＜0.05).There were no adverse reactions related to the drug use in two groups during the treatment period.Conclusion Trimetazidine Dihydrochloride in the treatment of patients with type 2 DM complicated with chronic heart failure can significantly improve cardiac function and reduce levels of FBG and HbA1c with significant effect,which is worthy of clinical promotion and application.

Key words： Trimetazidine Dihydrochloride Type 2 diabetes mellitus Chronic heart failure Cardiac function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIN Shao-hua
	CHEN Mei-qing

Cite this article:

LIN Shao-hua,CHEN Mei-qing. Clinical effect analysis of Trimetazidine Dihydrochloride in the treatment of patients with type 2 diabetes mellitus complicated with chronic heart failure[J]. 中国当代医药, 2018, 25(23): 158-161.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I23/158

[1]	梁静云，韦慧红.集束化护理在冠心病介入治疗患者二级预防中的效果[J].解放军预防医学杂志，2017，35（7）：820-821，836.
[2]	朱蕾.辛伐他汀联合盐酸曲美他嗪治疗糖尿病合并冠心病的临床疗效分析[J].中西医结合心血管病杂志，2017，5（3）：23.
[3]	张培培，黄榕.曲美他嗪治疗糖尿病合并慢性心功能不全患者的临床疗效观察[J].安徽医药，2018，22（2）：348-351.
[4]	廖清池，宋学璟，李琪，等.芪参益气滴丸联合曲美他嗪治疗糖尿病合并缺血性心肌病心力衰竭的疗效观察[J].中西医结合心血管病杂志，2017，5（24）：96-97.
[5]	中华医学会糖尿病学分会.中国2型糖尿病防治指南（2013 年版）[J].中华糖尿病杂志，2014，6（7）：447-498.
[6]	中华医学会心血管病学分会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志，2014，42（2）：98-122.
[7]	张莉，王秀琼.曲美他嗪治疗糖尿病伴冠心病患者的临床疗效[J].中国当代医药，2016，23（5）：125-127.
[8]	阿卜杜热西提?则亚维丁.冠心病合并糖尿病患者采用曲美他嗪治疗对其心绞痛持续时间的影响分析[J].中西医结合心血管病杂志，2016，4（32）：46.
[9]	张淑娟.曲美他嗪治疗冠心病合并糖尿病的临床应用效果分析[J].中西医结合心血管病杂志，2016，4（31）：93.
[10]	Gelosa P，Banfi C，Brioschi M.S35171 exerts protective effects in spontaneously hypertensive stroke-prone rats by preserving mitochondrial function[J].Eur J Pharmacol，2009，604（1-3）：117-124.
[11]	梁俊文，郭志强，林嘉敏，等.曲美他嗪对糖尿病性心肌病大鼠心肌损伤保护作用研究[J].现代中西医结合杂志，2015，24（13）：1378-1380.
[12]	Morozova TE，Ivanova EP，Rykova SM.Clinico-economical aspects of application of trimetazidine MB in patients with chronic heart failure and cardiac rhythm disturbances[J].Kardiologiia，2011，51（9）：35-41.
[13]	彭玉娟，谢亚芹，康大伟，等.曲美他嗪与雷米普利对慢性心力衰竭大鼠心肌组织转化生长因子β1表达的影响[J].中华老年心脑血管病杂志，2014，16（1）：21-24.
[14]	申丽锋，詹文彦，田国芳，等.保心安胶囊联合曲美他嗪片对2型糖尿病合并心力衰竭患者pro-BNP的影响研究[J].河北医药，2018，40（2）：183-187.
[15]	李雪霖，何金，田卓，等.Tei指数评价曲美他嗪治疗糖尿病心肌病慢性心力衰竭的临床研究[J].临床超声医学杂志，2017，19（7）：437-439.
[16]	Park JJ，Choi DJ，Yoon CH，et al.Prognostic value of C-reactive protein as an inflammatory and N-terminal probrain natriuretic peptide as a neurohumoral marker in acute heart failure （from the Korean Heart Failure Registry）[J].Am J Cardiol，2014，113（3）：511-517.
[17]	Den Engelsen C，Koekkoek PS，Gorter KJ，et al.High-sensitivity C-reactive protein to detect metabolic syndrome in a centrally obese population：a cross-sectional analysis[J].Cardiovasc Diabetol，2012，11（1）：25.
[18]	吴静.曲美他嗪治疗糖尿病合并冠心病的临床分析[J].中西医结合心血管病杂志，2015，3（32）：111-113.
[19]	Rantor PF，Lucien A，Kozak R，et al.The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain-3-ketoacyl coennzyme A thiolase[J].Circ Res，2000，86（5）：580-588.